期刊文献+

芪蛭肾安丸对5/6肾切除肾衰大鼠的肾保护作用

Renal protective effect Qizhishenan pills in 5/6 nephrectomy rats with renal failure
下载PDF
导出
摘要 目的观察芪蛭肾安丸对5/6肾切除肾衰大鼠的肾保护作用。方法 SD雄性大鼠随机分为正常对照组、模型对照组、芪蛭肾安丸(1.0 g/kg)组、芪蛭肾安丸(2.0 g/kg)组、芪蛭肾安丸(4.0 g/kg)组和尿毒清颗粒组,每组8只。5/6肾切除建立慢性肾衰竭(CRF)大鼠模型,给药组大鼠连续用药6周后,检测血脂,肾功能及尿量、蛋白尿的变化。结果与模型对照组比较,芪蛭肾安丸(1.0 g/kg、2.0 g/kg、4.0 g/kg组大鼠尿量明显增加(P<0.05),蛋白尿、BUN、Cr、TC、TG均明显减低(P<0.01)。结论芪蛭肾安丸对模型大鼠肾脏具有保护作用,它可能是通过调节脂代谢、降低蛋白尿而实现的。 Objective It is to observe the renal protective effect of Qizhi shenan pills in 5/6 nephrectomy rats with renal failure.Methods SD rats were randomly divided into normal control group,model control group,Qizhishenan pill(1.0 g/kg)group,Qizhishenan pill(2.0 g/kg)group,Qizhishenan pills(4.0 g/kg)group and Niaoduqing particle group,8 rats in each group.5/6 nephrectomy was used to establish chronic renal failure(CRF) rat model.After continuous medication of six weeks in drug administration group,the changes of serum lipids,renal function and urine volume,urinary protein were determined.Results Compared with model control group,urine volume increased significantly(P<0.05),urinary protein,BUN,Cr,TC and TG were significantly lower(P<0.01) in Qizhishenan pill groups including(1.0 g/kg,2.0 g/kg,4.0 g/kg).Conclusion Qizhishenan pills have a kidney protective effect for the rat models of CRF which may be achieved by regulating fat metabolism and reducing proteinuria.
出处 《现代中西医结合杂志》 CAS 2012年第29期3210-3211,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 芪蛭肾安丸 慢性肾衰竭 脂代谢紊乱 Qizhishenan pills chronic renal failure lipid metabolism disorders
  • 相关文献

参考文献2

二级参考文献25

  • 1刘华锋,王瑞强,姚翠微,梁东,唐德燊,陈孝文.“慢性肾衰基本方”对肾小管-间质纤维化防治作用的实验研究[J].中药药理与临床,2006,22(3):141-144. 被引量:5
  • 2贾秀琴,李雪梅.中药抗肾纤维化用药规律探析[J].中国中西医结合肾病杂志,2006,7(12):739-740. 被引量:31
  • 3Bramlage P,Thoenes M,Paar WD,et al.Albuminuria:an indicator of cardiovascular risk.Med Klin (Munich),2007,102(10):833-843; quiz 844-853.
  • 4Tanaka M,Seki G,Someya T,et al.Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy.Clin Dev Immunol,2011.470803.
  • 5Zhou YH,Tang LG,Guo SL,et al.Steroids in the treatment of IgA nephropathy to the improvement of renal survival:a systematic review and meta-analysis.PLoS One,2011,6(4):e18788.
  • 6Austin HA,Klippel JH,Balow JE,et al.Therapy of lupus nephritis:Controlled trial of prednisone and cytotoxic drugs.N Engl J Med,1986,314(4):614-619.
  • 7Appel GB,Contreras G,Dooley MA,et al.Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.J Am Soc Nephrol,2009,20(5):1103-1112.
  • 8Szeto CC,Kwan BC,Lai FM,et al.Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.Rheumatology (Oxford),2008,47(11):1678-1681.
  • 9Bao H,Liu ZH,Xie HL,et al.Successful treatment of class V+IV lupus nephritis with multitarget therapy.J Am Soc Nephrol,2008,19 (10):2001-2010.
  • 10Mann JF,Schmieder RE,McQueen M,et al.Renal outcomes with telmisartan,ramipril,or both,in people at high vascular risk (the ONTARGET study):a multicentre,randomised,double-blind,controlled trial.Lancet,2008,372(3):547-553.

共引文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部